PEDIATRIC ONCOLOGY GROUP

这项建议是要求支持继续参加 儿科肿瘤组（POG）这项合作研究致力于 化疗、免疫学和分子生物学的研究 治疗急性白血病和其他白血病的生物学方法 儿童肿瘤性疾病。 显著的无病生存率 在临床药理学方面取得了成就并做出了贡献， 肿瘤免疫学和癌症生物学。 然而，《圣经》的真实的目标 这些研究是通过治疗根除肿瘤性疾病。 正在设计研究以反映日益严重的攻击 在肿瘤细胞上。 合作小组技术允许迅速 对有希望的电极导线的合理尺寸进行系列评价， 化疗这些线索或新方法往往是由 该小组在临床肿瘤学方面的工作成果。 一个完整的 protocol通常建议在新的protocol中探索新的途径。POG 领导了急性淋巴细胞性白血病免疫表型的研究， 白血病、白血病细胞中NTX聚谷氨酸盐蓄积和N-myc 神经母细胞瘤中的基因扩增， 结果，然后将其纳入新的治疗方案， to improve提高survival生存of children儿童with cancer癌症. 司 加州大学圣地亚哥分校儿科血液学/肿瘤学 拥有24年的合作经验（10年在CALGB和14年在POG） 临床试验 在过去的5年中，4个联盟成员 332名患者接受了治疗和非治疗。 治疗研究和卫星，211名患者。 我们的调查人员 在12个委员会任职，设计/协调16项小组方案研究。 我们还为15个小组的出版物/演讲做出了贡献。 我们 研究人员将继续设计和主持治疗方案， 在委员会任职。余博士的实验室将继续探索新的 组用免疫抑制剂，并作为组参比品 实验室 我们计划继续积极参与所有阶段的工作 的POG活动。

This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities.